New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP089 at #EULAR2026 provides real-world data on biologic use after new cancer diagnoses in RA. Continuing biologics in early-stage cancer, & restarting them in many stage 2-3 cancers, was not associated with worse 5-year survival in this Japanese registry study. @RheumNow https://t.co/OdCPiCxFEq
Antoni Chan MD (Prof) synovialjoints
2 months 1 week ago
22% of psoriasis patients developed #PsAover 17 years of follow-up. PsA occurred in 44% of TNFi-treated vs only 9–14% of those on IL-23i or IL-12/23i. Time to discuss "preventive biologics" in PsO? Prospective controlled trials are needed Abstr#072 @RheumNow #EULAR2026
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2025 OP0127 Still trying to get my head around the flat line PBO response. In Sjogren pts with ESSDAI=>5, a Phase 3 RCT of Telitacicept (BAFF/APRIL-i) in China met all endpoints. ESSPRI improved too! Could be because strict concom DMARD inc. GC protocol @RheumNow https://t.co/FEhXfNPvfG
Antoni Chan MD (Prof) synovialjoints
2 months 1 week ago
In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-ILD risk, independent of MUC5B status. The effect size was similar to that seen in idiopathic pulmonary fibrosis. @RheumNow
Janet Pope Janetbirdope
2 months 1 week ago
#Autoimmune #progressive #pulmonary #fibrosis
Large Spanish registry
❎more mortality if not on #DMARDs
?underRx of proven #Rx with #antifibrotics
Median survival post #dx #PPF 7.8 yrs
Can we do better?
#ABST POS0430
@RheumNow #EULAR2026 https://t.co/gP7apxfEPS
sheila RHEUMarampa
2 months 1 week ago
Multiparametric renal MRI in LN:
Structural MRI can differentiate bet. active and stable dse
Exudative = active inflamm
In quanti analysis, low ADC values may reflect fibrosis.
A potential non-invasive biomarker?
OP092 @rheumNow #EULAR2026 https://t.co/IarTGOen7v
Aurelie Najm AurelieRheumo
2 months 1 week ago
DIPSA RCT: diet in PsA
92 pts 3 arms Mediterranean vs DASH low-calorie vs standard advice
Primary takeaway: amount of weight loss matters more than diet!
-All groups lost modest weight 1–2.5 kg
-All improved similarly in DAPSA -4 to -6 wk 24
-No differences for disease https://t.co/U0cxtdl2Yb
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP0112 at #EULAR2026: Real world RISE registry data shows incr use of semaglutide and tirzepatide across RMDs, particularly RA and PsA. Tirzepatide achieved greater weight loss than semaglutide, with ongoing analyses assessing effects on disease activity and function. @RheumNow
sheila RHEUMarampa
2 months 1 week ago
This retrospective cohort of NPSLE pts
showed clinical assocs with MRI findings: Pts w/ focal symptoms - abn MRI
Pts w/ diffuse symptoms - normal MRI except brain atrophy
Interesting to know how this can aid in future mgt strategies for NPSLE
OP093 @RheumNow #EULAR2026 https://t.co/omvdWk6EZK
Aurelie Najm AurelieRheumo
2 months 1 week ago
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6
Mrinalini Dey DrMiniDey
2 months 1 week ago
#OP087 explored cancer polygenic risk scores (PRS) in RA. RA was assoc with lower risks of breast and colorectal cancer across all PRS categories, while high prostate cancer PRS may identify RA patients with increased early prostate cancer diagnoses. @RheumNow #EULAR2026 https://t.co/WMqqSFADlW
EULAR – The European Alliance of Associations for Rheumatology – held its 2026 annual Congress in London, where gout was high on the agenda. Current guidelines recommend lifelong urate-lowering therapy (ULT) in a treat-to-target (T2T) strategy to maintain remission, although there is some scope for discussing tapering or discontinuation if remission is achieved.
Aurelie Najm AurelieRheumo
2 months 1 week ago
68Ga-RGD PET/CT in PsA reveals large chunk of “silent” synovitis
15 pts 1020 joints
35% affected joints clinically silent
PET signal correlation w/ disease burden:
DAPSA (ρ=0.66)
CRP (ρ=0.69)
Pilot study — not confirmed with US
Needs validation but intriguing signal
#OP068 https://t.co/nhS7PDZN0A
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2026 OP077 Another promising CAR-T in autoimmunity. In a Phase II study, Rap-Cel autologous CD19 CAR-T (shorter infusion time ~2d & low dose) vs traditional CAR-T showed drug-free improvement in N=6 #IIM & N=6 #SSc patients. Safety similar to other CAR-Ts @RheumNow https://t.co/byNn5X8JGh
